Anti-diabetes drug, metformin, drives metabolic reprogramming in tumor microenvironment, leading to sustained anti-tumor immunity.

○Heiichiro UDONO, Mikako NISHIDA

10:50 AM - 11:15 AM

[3AS-10-5] Anti-diabetes drug, metformin, drives metabolic reprogramming in tumor microenvironment, leading to sustained anti-tumor immunity.

○Heiichiro UDONO¹, Mikako NISHIDA¹ (1.Dept. Immunol., Okayama Univ.Grad.Sch.Med.)

CD8TILs, glycolysis, Oxphos, ROS

This archive has moved to the member page of The Molecular Biology Society of Japan.
Members can access the abstracts via links at the member page of the sites.
Please feel free to contact the journal offices for any inquiries.

The 43rd Annual Meeting of the Molecular Biology Society of Japan

[3AS-10-5] Anti-diabetes drug, metformin, drives metabolic reprogramming in tumor microenvironment, leading to sustained anti-tumor immunity.

Password